Enabled by the proprietary PurcisionTM technology, LSAMs of pure drug are suspended at time of use and delivered directly to the disease site where the particles are retained as a depot continuously releasing drug molecules as the particles dissolve.
Large Surface Area Microparticles (LSAMs)
Intratumoral
Peritumoral
Intraperitoneal
Resection bed
Intravesicular
Instillation
Inhalation
Intracystic
Topical
Advantages
High sustained local concentration
Continuous tumor kill
Immunogenic effect
Gradual subtoxic clearance
Composition of matter patent on LSAMs protects particle regulatory specifications:
Size
Surface Area
Density
Dissolution
LSAMs are Superior to IV Drugs for Intratumoral Delivery
Taxane Solution for Injection Tumor Site
Paclitaxel or docetaxel injections are designed for IV administration and rapidly diffuse out of the tumor if injected intratumorally.
LSAM-PTX and LSAM-DTX are designed for local administration and become entrapped in the tumor allowing for therapeutic drug release
Tumor tissue concentration of LSAM-PTX and LSAM-DTX versus comparators all given intratumorally in a mouse model
Proprietary PurcisionTM Platform Large Surface Area Microparticle LSAM Production
API Crystals
Large and bulky crystals
Large distribution around particle size mean with large clumps
Poor uniformity of suspensions
Poor drug release due to small surface area
Limited to dissolution in solvent as a solution for IV delivery
API crystals dissolved in organic solvent and injected into precipitation chamber
Sonicated into small uniform droplets via sonic probe
Solvent stripped away from droplets via supercritical fluid carbon dioxide
Stable microparticles of pure drug precipitated and collected on harvesting filters
Platform for multiple drug classes
LSAMs
Narrow particle size distribution around mean
Microparticles suspended in saline-based fluid for local delivery
Excellent suspension uniformity
Disproportionately large surface area to particle size ratio allows for:
Particle entrapment
Therapeutic drug release
Growing Global IP PortfolioIP Protection Like A New Chemical Entity